Asep Inc. obtains patent approval for its sepsis diagnostic technology in 13 European countries and Australia

Asep Inc. obtains patent approval for its sepsis diagnostic technology in 13 European countries and Australia

VANCOUVER, B.C., November 7, 2022 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce that the Company’s sepsis diagnostic technology, called SepsetRE MThas successfully received patent approval in 13 European countries, as well as in Australia. The Company received confirmation of its European Patent (EP) 3117030 from its patent attorneys on August 29, 2022and this patent was later validated in Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Swiss and the United Kingdom, which represents 400 million people. The Company also obtained a patent in Australia (Australian Patent No. AU2020201564B2), issued on July 16, 2022.

The patents, exclusively licensed to Sepset Biosciences Inc., a subsidiary of Asep Inc., validate the company’s unique and clinically viable AI-based approach to the diagnosis of sepsis, a disease that globally causes more than 11 million deaths per year. . The technology, called Sepsetemergenciesis a blood-based gene expression assay developed under the leadership of prominent UBC microbiologist and founding director and current CEO of Asep Inc., Dr. Robert E. W. Hancock. The test enables early and accurate diagnosis of severe incidences of the deadly disease sepsis, which is also the cause of death in the majority of patients with severe COVID-19.

The patents also provide a strong foundation for the company’s business as the test is in advanced development and in preparation for formal 510(k) clinical trials. from Sepsetemergencies The signature has already been validated and refined in over 700 sepsis and severe COVID-19 patients to date, the company is looking to duplicate this in a formal trial. In the diagnostic area, the 510(k) pathway involves a single clinical trial that, if successful, will lead to approval by the US Food and Drug Administration (FDA). Once approved, the test will be commercialized for use in emergency rooms and intensive care units worldwide, enabling clinicians to make early, informed decisions about patient care that will improve prognosis and survival.

the sepsetemergencies The test detects the dysfunctional immune response underlying sepsis when patients first enter the emergency room. The test is a blood-based gene expression assay that is simple to implement using equipment available in most hospital laboratories, and results are obtained in approximately 60 to 90 minutes. Current diagnostic tools provide results after approximately 8 to 36 hours, often delaying the start of treatment. Sepsetemergencies it is designed to allow doctors to quickly predict the severity of the disease and thus trigger urgent treatment of the patient. The patent license agreement grants Asep Inc. subsidiary Sepset Biosciences Inc. exclusive worldwide rights to develop the sepsis severity signature into a diagnostic test and bring the test to market.

CEO Dr. Robert E. W. Hancock stated, “Patents are the lifeblood of biotechnology. This validates the novelty of our technology in major markets.”

Tim Murphythe COO, commented: “The expansion of Asep Inc.’s patent coverage in Europe Y Australia represents an important step for the company towards the commercialization of Sepsetemergencies Test.


Asep Medical Inc. ( is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) that are in the advanced development of proprietary diagnostic tools, enabling early and timely identification of severe sepsis, as well as therapies for spread spectrum. Agents to treat multidrug-resistant biofilm infections.

Sepset Biosciences Inc. ( is developing a diagnostic technology involving a patient gene expression signature that predicts severe sepsis, one of the important diseases leading to antibiotic failure, as antibiotics are the main treatment for sepsis. Despite this, sepsis is responsible for almost 20% of all deaths on the planet. the sepsetemergencies The test is a blood-based gene expression assay that is easy to implement and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in that it enables diagnosis of severe sepsis within 1-2 hours of first clinical presentation (i.e., in the emergency room), whereas other diagnostics only provide diagnosis after from 24 to 36 hours. Asep Inc. believes this will enable clinicians to make critical early decisions regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.

ABT Innovations Inc. ( Peptide technology covers a wide range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ENT, sinus, orthopedic, etc.), anti-inflammatories, anti-infective immunomodulators and vaccine adjuvants.


This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are often characterized by words such as “anticipates”, “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may” , “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements include, but are not limited to, the successful completion of clinical testing of our sepsis diagnostic test and its anticipated submission for regulatory approval; and conducting preclinical studies on our main treatment, with the expectation that this will lead to accelerated clinical trials. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this press release. Forward-looking statements are based on management’s opinions and estimates as of the date the statements are made and are subject to a variety of risks (including risk factors identified in Asep Medical Inc.’s prospectus dated November 9, 2021) available for review under the Company profile at and uncertainties and other factors that could cause actual events or results to differ materially from those projected in forward-looking statements. Asep Medical Inc. has no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE ASEP Medical Holdings Inc.

Leave a Comment